Current market catalysts

Robinhood Expands Prediction Markets Push With Crypto.com, OG Deal

Robinhood strikes a multiyear Crypto.com deal to add OG contracts and take minority stakes as its prediction-market business keeps growing.

Qualcomm CFO Says Deal With Amazon Positions Qualcomm To Deliver Strong YoY Rev Growth From FY27 To FY28

HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $20 Price Target

Ladenburg Thalmann Initiates Coverage On Hawaiian Electric Indus with Sell Rating, Announces Price Target of $7

HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

TeraWulf shares are trading higher after Freedom Capital initiated coverage on the stock with a Buy rating and announced a $19 price target.

HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target

HSBC Reiterates Buy on Apple, Maintains $366 Price Target

JP Morgan Maintains Overweight on FedEx, Lowers Price Target to $400

What's Going On With Shopify Stock Tuesday?

Shopify (SHOP) fell nearly 8% as investors rotated away from high-multiple growth stocks despite strong Q2 earnings. Learn more.

Astrazeneca Secures FDA Approval for New Breast Cancer Treatment

AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 trial data for lung cancer and COPD.

JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

Oddity Tech Q2 Earnings Preview: Expect CPA Pressure With Early Inflection Signs

Oddity Tech shares fall ahead of Q2 results. Needham analyst expects CPA pressure but signs of stabilization.

K Wave Media Announces Name Change To Nexus Advanced Technologies And Nasdaq Ticker Change From KWM To NXAT, Effective At Market Open September 9

Visa Brings Onchain Lending Closer to Everyday Stablecoin Payments

Visa introduces an onchain credit model combining VisaNet settlement data with blockchain lending to help stablecoin-linked card programs access working capital.

Constellation Brands Exec Says Company Will See Little Bit Of Gross Profit Margin Pressure In Second Half Of The Year

Raymond James Upgrades Airbnb to Outperform, Announces $200 Price Target

$1000 Invested In Jabil 10 Years Ago Would Be Worth This Much Today

Jabil (NYSE:JBL) has outperformed the market over the past 10 years by 17.45% on an annualized basis producing an average annual return of 31.12%. Currently, Jabil has a market capitalization of $32.69 billion. Buying

Jefferies Maintains Buy on Roivant Sciences, Raises Price Target to $52

Jefferies Maintains Buy on Robinhood Markets, Raises Price Target to $140

HF Sinclair shares are trading higher after UBS maintained a Buy rating on the stock and raised its price target from $105 to $126.

Can Visa's Agentic Ready Program Answer The Citrini Bear Case?

Visa Inc. (NYSE:V) expects millions of consumers to use AI agents to complete purchases by the 2026 holiday season. The question for investors is what happens when those agents start deciding not only what to buy, but

Rothschild & Co Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67

WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5

Raymond James Downgrades Phreesia to Market Perform

Forget XRP, Privacy Coins Are the 2026 Standout Trade—One Is Up 2,400%

Privacy coins lead crypto’s recovery, up 213%, with Zcash surging 2,496% and traders projecting $5,000-$10,000 if Bitcoin stays strong.

Here's How Much $1000 Invested In American Express 5 Years Ago Would Be Worth Today

American Express (NYSE:AXP) has outperformed the market over the past 5 years by 3.71% on an annualized basis producing an average annual return of 15.16%. Currently, American Express has a market capitalization of

What's Going On With Super Micro Computer Stock Tuesday?

Why is Super Micro (SMCI) stock outperforming the market? Discover key technical levels, growth ratings, and analyst forecasts.

Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.

U.S. Treasury Secretary Bessent Says We Must Keep Moving Forward With AI, As China Will Not Slow Down